Subscribe To

Price Alert Latest News Economic Calendar News

BCYC / Why Bicycle Therapeutics Stock Is Soaring Today

Bicycle Therapeutics plc (NASDAQ: BCYC) has announced interim Phase 1 results from the Phase 1/2 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors. The data will be presented at the 2022 American Association for Cancer Research. Read More

Demo Live Account See Partner Details

Content Topics

Bicycle

Therapeutics

Stock

Soaring

Today

BCYC

Posted: Apr 8 2022, 15:07

Author Name: Benzinga

BCYC News

By Zacks Investment Research
September 12, 2023

Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to s

By Zacks Investment Research
September 12, 2023

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimat

By The Motley Fool
September 11, 2023

Why Shares of Bicycle Therapeutics Were Rising on Monday

Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech.

By Seeking Alpha
July 31, 2023

Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due

Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-

By Zacks Investment Research
July 14, 2023

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimat

By The Motley Fool
July 13, 2023

Why Bicycle Therapeutics Stock Raced Ahead Today

The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue.

By Seeking Alpha
May 14, 2023

Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet

BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may

By Zacks Investment Research
May 4, 2023

Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet

The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that t

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.